Relay Therapeutics, Inc (RLAY)

Etorro trading 970x250
Relay Therapeutics, Inc (RLAY) Logo

About Relay Therapeutics, Inc

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its product candidates include RLY-1971, an oral small molecule inhibitor of the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 (SHP2) that is in Phase 1 dose escalation studies in patients with advanced or metastatic solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth factor receptor 2 (FGFR2) for patients with advanced solid tumors having oncogenic FGFR2 alterations; and RLY-PI3K1047, a lead compound that targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts. Address: 399 Binney Street, Cambridge, MA, United States, 02139

Relay Therapeutics, Inc News and around…

Latest news about Relay Therapeutics, Inc (RLAY) common stock and company :

56 Biggest Movers From Yesterday
24 Nov, 2021 FinancialContent

Gainers Aptevo Therapeutics Inc. (NASDAQ: APVO) shares jumped 162.8% to close at $17.03 after the company announced a clinical ...

12 Health Care Stocks Moving In Tuesday's Intraday Session
23 Nov, 2021 FinancialContent

Gainers Pasithea Therapeutics (NASDAQ:KTTA) stock moved upwards by 228.5% to $7.26 during Tuesday's regular session. The company's ...

36 Stocks Moving In Tuesday's Mid-Day Session
23 Nov, 2021 FinancialContent

Gainers Pasithea Therapeutics Corp. (NASDAQ: KTTA) shares jumped 216.6% to $7.00 after the company announced its subsidiary ...

Notable Relay Therapeutics Insider Trades $890K In Company Stock
17 Nov, 2021 Yahoo! Finance

Thomas Catinazzo, Insider at Relay Therapeutics (NASDAQ:RLAY), made a large buy and sell of company shares on November 15, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Thomas Catinazzo exercised options to purchase 22,500 Relay Therapeutics shares at a price of $4.12 per share for a total of $92,700 on November 15. They then sold their shares on the same day in the open market. They sold at a price of $35.40 to raise a

How Many Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Do Institutions Own?
16 Nov, 2021 Yahoo! Finance

If you want to know who really controls Relay Therapeutics, Inc. ( NASDAQ:RLAY ), then you'll have to look at the...

Overview Of Value Stocks In The Healthcare Sector
15 Nov, 2021 FinancialContent

The Meaning Behind Value Stocks A value stock traditionally has a lower price when compared to stock prices of companies in the same ...

Relay Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights
10 Nov, 2021 Yahoo! Finance

CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported third quarter 2021 financial results. “It’s been a very productive year at Relay Therapeutics. We have delivered on all of our key goals set out at our IPO in July 2020 and have proven our ability to effectively advance our clinical tria

Relay Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corporate Highlights
04 Nov, 2021 Yahoo! Finance

CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report third quarter 2021 financial results after the close of market on Wednesday, November 10, 2021. The company will not be conducting a teleconference in conjunction with its financial results press release. About Relay Therapeutics Relay

Section 32 Raises $740 Million Venture Fund
04 Nov, 2021 Yahoo! Finance

Section 32 announced today the closing of its fourth fund, raising approximately $740 million from returning and new investors. Investors in Fund 4 include leading philanthropic and non-profit organizations, educational endowments and foundations, and leaders from the technology and healthcare sectors. Section 32 Fund 4 will support companies across all stages that are pioneering innovations at the forefront of technology and healthcare. With the closing of its oversubscribed Fund 4 and to suppo

A Look Into Healthcare Sector Value Stocks
01 Nov, 2021 FinancialContent

Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that ...

J.P. Morgan Sees These 3 ‘Strong Buy’ Stocks Climbing Over 50%
27 Oct, 2021 Yahoo! Finance

2021 has been marked by a litany of worries; from inflation getting out of hand, to the Fed’s tapering of its stimulus program, to fears of a slowdown in economic recovery amidst global shortages, supply chain issues and rising energy prices. Still, all these haven’t affected the stock market’s performance, with the main indexes constantly notching new highs. Even after September’s sharp drop, October has seen a swift bounce back. So, where to now? J.P. Morgan appears confident the bull run has

10 Pharma Stocks to Buy According to Mark Lampert’s Biotechnology Value Fund
27 Oct, 2021 Yahoo! Finance

In this article, we examined Mark Lampert’s investment philosophy and decades of experience in the biotechnology space. We also reviewed 10 pharma stocks to buy according to Mark Lampert’s Biotechnology Value Fund. You can skip our detailed discussion and jump directly to 5 Pharma Stocks to Buy According to Mark Lampert’s Biotechnology Value Fund. Mark […]

51 Biggest Movers From Friday
18 Oct, 2021 FinancialContent

Gainers LM Funding America, Inc. (NASDAQ: LMFA) shares jumped 38.1% to close at $4.75 on Friday after declining around 15% on ...

12 Health Care Stocks Moving In Friday's Intraday Session
15 Oct, 2021 FinancialContent

Gainers Statera BioPharma (NASDAQ:STAB) shares rose 16.9% to $3.32 during Friday's regular session. The market value ...

Why Relay Therapeutics Is Up 30% This Week
15 Oct, 2021 FinancialContent

Interim trial data suggests this innovative biotech start-up is on the right track.

44 Biggest Movers From Yesterday
15 Oct, 2021 FinancialContent

Gainers Benessere Capital Acquisition Corp. (NASDAQ: BENER) shares jumped 66.5% to close at $0.4530 on Thursday. Grove, Inc. ...

12 Health Care Stocks Moving In Thursday's Intraday Session
14 Oct, 2021 FinancialContent

Gainers NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 37.92% to $13.02 during Thursday's regular session. As of 12:30 EST, ...

Octant Bio Appoints Industry Veteran Mark Murcko as Strategic Advisor and Board Member
14 Oct, 2021 FinancialContent

Today, Octant, a therapeutics company integrating novel high-throughput experimental technologies with computation to solve complex challenges in drug discovery, announced the appointment of Mark Murcko as Strategic Advisor and Board Member. Murcko brings over three decades of industry experience, having been at the center of many transformational biotech efforts, most recently as founding CSO and Board Member of Dewpoint Therapeutics. Murcko is working closely with the company to scale Octant to its next phase of growth and further develop its chemistry platform.

50 Biggest Movers From Yesterday
14 Oct, 2021 FinancialContent

Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares surged 105.1% to close at $14.79 on Wednesday after Oppenheimer initiated ...

12 Health Care Stocks Moving In Wednesday's Intraday Session
13 Oct, 2021 FinancialContent

Gainers Statera BioPharma (NASDAQ:STAB) shares increased by 16.92% to $3.16 during Wednesday's regular session. The ...

Relay Therapeutics Announces Pricing of Public Offering of Common Stock
13 Oct, 2021 Yahoo! Finance

CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today the pricing of an underwritten public offering of 13,207,547 shares of its common stock at a public offering price of $26.50 per share. Relay Therapeutics also granted the underwriters a 30-day option to purchase up to an additional 1,9

Analysts Predict 60% Upside For NIFE
12 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Direxion Fallen Knives ETF ETF (NIFE), we found that the implied analyst target price for the ETF based upon its underlying holdings is $109.87 per unit.

The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
12 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

A Peek Into The Markets: US Stock Futures Mostly Flat Ahead Of Earnings
12 Oct, 2021 FinancialContent

Pre-open movers U.S. stock futures traded mostly flat in early pre-market trade after the Dow Jones dropped 250 points in the ...

5 Stocks To Watch For October 12, 2021
12 Oct, 2021 FinancialContent

Some of the stocks that may grab investor focus today are: Wall Street expects Fastenal Company (NASDAQ: FAST) to report quarterly ...

Relay Therapeutics Announces Proposed Public Offering of Common Stock
11 Oct, 2021 Yahoo! Finance

CAMBRIDGE, Mass., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today that it has commenced an underwritten public offering of $350 million of shares of its common stock. Relay Therapeutics also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the

Relay Therapeutics Highlights Interim Data From Bile Duct Cancer Trial
08 Oct, 2021 FinancialContent

Relay Therapeutics Inc(NASDAQ: RLAY) hasannounced an interim data Phase 1 trialof RLY-4008 in FGFR2-altered ...

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
08 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Relay Therapeutics Announces Interim Clinical Data that Support RLY-4008 as a Highly Selective FGFR2 Inhibitor
08 Oct, 2021 Yahoo! Finance

Interim data suggest that RLY-4008 is a highly selective FGFR2 inhibitor that has not shown to be limited by off-target toxicities of hyperphosphatemia (FGFR1) and diarrhea (FGFR4) RLY-4008 demonstrated tumor shrinkage in all six pan-FGFR treatment-naïve FGFR2 fusion positive cholangiocarcinoma patients with three achieving confirmed partial responses Interim data support potential clinical benefits of optimized inhibition of FGFR2 regardless of alteration (fusions, mutations, and amplifications

45 Biggest Movers From Yesterday
08 Oct, 2021 FinancialContent

Gainers Camber Energy, Inc.. (NYSE: CEI) shares surged 95.9% to close at $1.78 on Thursday after dipping over 40% on Wednesday. ...

Relay Therapeutics, Inc (RLAY) is a NASDAQ Common Stock listed in , ,

970x250